Predicine Announces New Study Published in The New England Journal of Medicine Demonstrating Clinical Utility of its MRD Liquid Biopsy Assay in Supporting Genentech’s Phase 1 Clinical Trial of Divarasib
20. September 2023 13:12 ET
|
Predicine
HAYWARD, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Predicine, Inc., a pioneer in the field of liquid biopsy, announced a new study published in The New England Journal of Medicine (NEJM),...
Predicine to Introduce PredicineALERT™ MRD Assay and Present Two ctDNA Studies in Genitourinary Cancers at AUA 2023 Annual Meeting
28. April 2023 17:42 ET
|
Predicine
HAYWARD, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announced today that it will present two studies and introduce PredicineALERT™ Minimal Residual...
Predicine to Introduce PredicineALERT™ MRD Assay and Present Twelve Posters at AACR 2023 Conference
14. April 2023 16:47 ET
|
Predicine
HAYWARD, Calif., April 14, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announced today that it will present data from 12 studies and introduce PredicineALERT™, a...
Predicine to Present Four Studies at 2023 ASCO Genitourinary (GU) Symposium Highlighting the Technical and Clinical Utility of Predicine’s Liquid Biopsy Based Assays
16. Februar 2023 16:05 ET
|
Predicine
HAYWARD, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, is committed to advancing genitourinary (GU) cancer detection and treatment decisions through its...
Predicine to Introduce PredicineCOMPLETE™, its Genome-Wide Liquid Biopsy Solution, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
10. November 2022 21:00 ET
|
Predicine
SILICON VALLEY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announces the introduction of PredicineCOMPLETE™, the organization’s most comprehensive...
Predicine’s Liquid Biopsy Next-Generation Sequencing (NGS) Assay is Granted Breakthrough Device Designation by U.S. Food and Drug Administration
20. September 2022 09:00 ET
|
Predicine
HAYWARD, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company committed to advancing precision medicine in oncology and infectious diseases, announced...
Predicine to Present New Data at ESMO 2022 Demonstrating the Utility of its Portfolio of Liquid Biopsy Tests for Cancer Patients
08. September 2022 16:00 ET
|
Predicine
SILICON VALLEY, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company, announced today that it will present four posters at the ESMO conference being held...
Predicine Expands to Europe with the recently launched CE-Marked cfDNA Assay PredicineCARE™ for Genomic Profiling in Blood and Urine
09. August 2022 08:00 ET
|
Predicine
SILICON VALLEY, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company, has launched its CE-marked PredicineCARE™ for genomic profiling in blood and urine....
Predicine Expands Its Nationwide COVID-19 Testing Capability Through the Recent FDA EUA Authorization of Predicine SARS-CoV-2 RT-PCR Test and Self-Collection Kit
25. Juli 2022 08:00 ET
|
Predicine
SILICON VALLEY, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company committed to advancing precision medicine in oncology and infectious diseases, announced...